CALL US NOW 0207 939 0780
PLEASE DONATE

HEALTHCARE

UK launches FibCLOT®▼ LFB’s human fibrinogen concentrate

LFB Biopharmaceuticals announced today the UK launch of FibCLOT, its human fibrinogen concentrate. This follows the granting of a UK Marketing Authorisation in April 2016, after a decentralised application to the Regulatory Authorities in Europe, and offers increased therapeutic choices for affected patients. FibCLOT® is indicated for the treatment and perioperative

Read More

Direct-acting Antiviral (DAA) treatment for Hepatitis C risks Hepatitis B reactivation

New guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) advises that all hepatitis C patients should be screened for hepatitis B before starting treatment with new Direct-acting Antivirals (DAAs). If patients are infected with both viruses this does not preclude treatment but this should be monitored and managed.

Read More